Cardiovascular toxicology (Cardiovasc Toxicol)

Journal PubWeight™ 401.34‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 The NF-kappaB regulatory network. 2006 2.25
2 The correlation between prolonged corrected QT interval with the frequency of respiratory arrest, endotracheal intubation, and mortality in acute methadone overdose. 2014 1.99
3 A case of caffeine-induced coronary artery vasospasm of a 17-year-old male. 2012 1.70
4 Oxidative stress and diabetic cardiomyopathy: a brief review. 2001 1.59
5 A case of acute cardiomyopathy and pericarditis associated with methylphenidate. 2009 1.48
6 A prospective study on electrocardiographic findings of patients with organophosphorus poisoning. 2011 1.43
7 Values of using QTc and N-terminal fragment of B-type natriuretic peptide as markers for early detection of acute antipsychotic drugs-induced cardiotoxicity. 2011 1.40
8 Questionable conclusions in the article "Cardiovascular toxicity of Citrus aurantium in exercised rats". 2013 1.39
9 Cell death and diabetic cardiomyopathy. 2003 1.32
10 Dioxin exposure is an environmental risk factor for ischemic heart disease. 2001 1.27
11 Nanoparticle inhalation impairs coronary microvascular reactivity via a local reactive oxygen species-dependent mechanism. 2010 1.27
12 HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. 2004 1.25
13 Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. 2007 1.20
14 Molecular and cellular mechanisms of anthracycline cardiotoxicity. 2007 1.17
15 Acute cardiovascular toxicity of sterilizers, PHMG, and PGH: severe inflammation in human cells and heart failure in zebrafish. 2013 1.17
16 Differential cardiopulmonary effects of size-fractionated ambient particulate matter in mice. 2010 1.14
17 Role of mtDNA lesions in anthracycline cardiotoxicity. 2007 1.14
18 Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. 2007 1.13
19 Role of anthracyclines in the era of targeted therapy. 2007 1.13
20 NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? 2003 1.12
21 Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? 2007 1.12
22 Huffing-induced cardiomyopathy: a case report. 2012 1.11
23 The prevalence of type 2 diabetes and hypertension in Uygur and Kazak populations. 2008 1.11
24 Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. 2004 1.11
25 Nicotine enhances human vascular endothelial cell expression of ICAM-1 and VCAM-1 via protein kinase C, p38 mitogen-activated protein kinase, NF-kappaB, and AP-1. 2006 1.11
26 Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. 2005 1.11
27 Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. 2004 1.11
28 Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide. 2008 1.10
29 Different global gene expression profiles in benzo[a]pyrene- and dioxin-treated vascular smooth muscle cells of AHR-knockout and wild-type mice. 2004 1.08
30 With which mechanism the overuse of energy drinks may induce acute myocardial ischemia? 2012 1.08
31 Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation. 2004 1.08
32 Elevations in cardiac troponin measurements: false false-positives: the real truth. 2001 1.08
33 Modification of environmental toxicity by nutrients: implications in atherosclerosis. 2005 1.07
34 The effect of saffron consumption on biochemical and histopathological heart indices of rats with myocardial infarction. 2010 1.07
35 Aryl hydrocarbon receptor null mice develop cardiac hypertrophy and increased hypoxia-inducible factor-1alpha in the absence of cardiac hypoxia. 2002 1.07
36 Heart rate variability in rodents: uses and caveats in toxicological studies. 2007 1.07
37 Letter to the editor in response to: The correlation between prolonged corrected QT interval with the frequency of respiratory arrest, endotracheal intubation, and mortality in acute methadone overdose. 2014 1.06
38 Genotyping the risk of anthracycline-induced cardiotoxicity. 2007 1.06
39 Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. 2001 1.05
40 Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. 2007 1.04
41 Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. 2005 1.04
42 NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor? 2005 1.04
43 Quo vadis: whither homocysteine research? 2009 1.04
44 Cardiac safety of liposomal anthracyclines. 2007 1.03
45 Mitochondrial involvement in cardiac apoptosis during ischemia and reperfusion: can we close the box? 2009 1.02
46 Perinatal tobacco smoke exposure increases vascular oxidative stress and mitochondrial damage in non-human primates. 2010 1.01
47 Cardiovascular toxicities upon manganese exposure. 2005 1.01
48 Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral agents. 2004 1.01
49 Increase in cardiovascular pathology in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,3',4,4',5-pentachlorobiphenyl. 2003 1.01
50 Arsenic exposure and cardiovascular disorders: an overview. 2009 1.00
Next 50